Table 1. Summary of first-line therapy for exacerbations in the outpatient setting and immediately post exacerbation.
| Initial prescription (outpatient), %a | Following an acute exacerbation, %a | |
|---|---|---|
| Inhaled therapies | ||
| SABA | 91.7 | 85.7 |
| SAMA | 57.7 | 46.7 |
| LABA | 57.7 | 65.3 |
| LAMA | 59.2 | 42.4 |
| ICS/LABA | 38.2 | 51.9 |
| LABA/LAMA | 58.2 | 79.8 |
| Nebulization | ||
| SABA | 90.9 | 64.0 |
| SAMA | 84.4 | 61.9 |
| Corticosteroids | 37.0 | 18.3 |
| Systemic corticotherapy | 68.5 | 21.7 |
| Antibiotic therapy | 87.9 | 40.5 |
| Diuretics | 14.5 | 5.9 |
| Bronchial drainage physiotherapy | 86.5 | 85.6 |
| Prevention LMWH | 5.8 | 9.3 |
| Mucomodulators | 19.8 | 11.4 |
aPercentage of respondents replying ‘yes’ to whether they prescribe a particular therapy in a particular setting (from a yes/no option).
ICS, inhaled corticosteroid; LABA, long-acting β2 agonists; LAMA, long-acting muscarinic antagonists; LMWH, low-molecular-weight heparin; SABA, short-acting β2 agonists; SAMA, short-acting muscarinic antagonists.